

WFS1 E680A — Wolframin

Glutamate → Alanine at position 680 in lumenal domain. ClinVar Conflicting including monogenic diabetes + Wolfram. AlphaMissense 0.34 (below threshold) — AM under-call. DynaMut2 $\Delta\Delta G$ -0.23 kcal/mol. Same position as E680Q — second substitution at 680.

IDENTITY

Variant	E680A (p.Glutamate680Alanine)
DNA change	c.2039A>C
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV000286507
Amino acid change	Glutamate (E) → Alanine (A) — small negatively-charged carboxylate replaced by small methyl-bearing hydrophobic. Charge lost + side chain reduced.

STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 680	84.12 HIGH CONFIDENCE
Domain	C-terminal lumenal domain (653-869)
Position context	C-terminal lumenal domain · position 680 (pLDDT 84).
IDR flag	No — pLDDT well above 50 threshold

Position 680 same neighbors as E680Q: THR681 (2.5 Å), LYS679 (2.5 Å — wild-type salt-bridge partner), ALA677 (4.0 Å), ARG676 (4.1 Å — second nearby basic). E680A is more drastic than E680Q — eliminates the charge AND removes the side chain (compared to E680Q which kept H-bonding capacity through the amide). The E680-K679 salt bridge is lost entirely. The R676 nearby basic loses its electrostatic counterpart through this position. AlphaMissense's 0.34 is below threshold (AM under-call); monogenic diabetes + Wolfram confirm pathogenicity.

COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE 0.342 am_class: Amb — threshold > 0.564	DYNAMUT2 $\Delta\Delta G$ -0.23 kcal/ mol Destabilising · Job 177992493528	PLDDT (ALPHAFOLD) 84.12 high confidence
--	---	--

CLINICAL EVIDENCE

ClinVar classification

CONFLICTING CLASSIFICATIONS OF PATHOGENICITY

Review status

criteria provided, conflicting classifications

Last evaluated

2026/01/30 00:00

Inheritance

Multi-phenotype.

WFS1 variant landscape

E680A is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar)

- Monogenic diabetes
- Wolfram syndrome 1

RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$ + binding site affected → CATEGORY 3 – docking experiments $\Delta\Delta G$ 2–4 → CATEGORY 2 – pharmacological chaperones $\Delta\Delta G > 4$ → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

Category 3/4 — Most Druggable (AM under-call). $|\Delta\Delta G| = 0.23$. AlphaMissense 0.34 below threshold but monogenic diabetes + Wolfram confirm pathogenicity.

Mechanism: complete loss of E680-K679 salt bridge plus side-chain volume reduction. Therapeutic strategy: same K679 microregion as E680Q.

E680A + E680Q at same position — both pathogenic at the K679 salt-bridge partner site.

